Physician profile
Dylan Zini
NPI 1144632290
$1,826.89
in general payments reported to CMS, 2019-2025
20 companies · $748 in 2025
The $748 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.64 · 2020: $13.20 · 2021: $43.26 · 2022: $28.98 · 2023: $160 · 2024: $816 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,723.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $302.29 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $273.86 | 2024-2025 | |
| Lilly USA, LLC | $231.84 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals Lp | $196.30 | 2023-2025 | Airsupra, Farxiga |
| Amgen INC. | $158.56 | 2024-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $131.79 | 2022-2025 | |
| Glaxosmithkline, LLC. | $78.80 | 2020-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astellas Pharma US INC | $70.66 | 2024-2025 | Veozah |
| Exact Sciences Corporation | $68.79 | 2024-2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $66.99 | 2024-2025 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $44.52 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $39.93 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Gilead Sciences, INC. | $34.03 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.83 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.74 | 2024 | Xarelto |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $17.29 | 2025 | Gemtesa |
| Viiv Healthcare Company | $17.25 | 2023 | Apretude |
| Dexcom, INC. | $16.82 | 2025 | Dexcom G6 Transmitter |
| Eisai INC. | $14.43 | 2021 | |
| Currax Pharmaceuticals LLC | $13.17 | 2024 | Contrave, Onzetra Xsail |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dylan Zini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.